We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AZD1222, which is not authorized in the U.S., is currently approved for use in the UK and EU, while Valneva is not yet approved for use anywhere. Read More
Liver cancer patients who received AstraZeneca’s blockbuster human monoclonal antibody Imfinzi (durvalumab) paired with the company’s anti-CTLA4 antibody tremelimumab in a phase 3 trial lived longer. Read More
CRISPR Therapeutics’ off-the-shelf CAR-T treatment conferred clinical benefits similar to those achieved with CAR-T treatments derived from the patients’ own cells, posting a 58 percent overall response and 38 percent complete response rate in a small series of patients with large B-cell lymphoma. Read More
Real-world evidence demonstrated that a drug prescribed to treat swelling and high blood pressure could help reverse the effects of Alzheimer’s disease, claimed researchers from the San Francisco, Calif.-based Gladstone Institutes and University of California, San Francisco (UCSF). Read More
The neurodegenerative disease drug development pipeline is full, but getting investigative drugs over the FDA finish line is both a biological and regulatory challenge. Read More
An investigation is underway to further characterize the abnormality, including any potential relationship to gene editing, the company said. Read More
AstraZeneca announced that its COVID-19 long-acting antibody (LAAB) combination, AZD7442, significantly reduced severity of COVID-19 as well as death in a phase 3 trial. Read More
Gantenerumab, Roche’s entry into the anti-amyloid antibody space, has secured FDA’s Breakthrough Therapy designation for treatment of Alzheimer’s disease (AD). Read More